ERBB2 and breast cancer: In this sense, an important randomized phase III trial, BOLERO-3, has demonstrated the PFS benefit of the addition of everolimus to trastuzumab plus vinorelbine in HER2 locally advanced or metastatic BC resistant to trastuzumab (NCT01007942) [137].